Matrix Metalloproteinases Increase Because of Hypoperfusion in Obstructive Hypertrophic Cardiomyopathy

Xuanye Bi1, Chengzhi Yang1, Yunhu Song1

  • 1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Abstract

Insights

In hypertrophic cardiomyopathy, high plasma ratios of PICP/ICTP and MMP-2/TIMP-1 predict adverse cardiovascular outcomes. These biomarkers indicate poor prognosis in patients with obstructive hypertrophic cardiomyopathy.

Area of Science:

  • Cardiology
  • Biomarkers
  • Pathophysiology

Background:

  • Myocardial fibrosis (MF) is linked to microvascular dysfunction in hypertrophic cardiomyopathy.
  • Matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs) influence collagen degradation and MF development.

Purpose of the Study:

  • Investigate relationships between MF, microvascular rarefaction, and MMPs.
  • Assess prognostic value of MF-related circulating biomarkers in obstructive hypertrophic cardiomyopathy (HOCM).

Main Methods:

  • Analyzed myocardial samples from 55 HOCM patients post-surgery for fibrosis and microvascular density.
  • Measured myocardial and plasma levels of MMP-2, MMP-9, TIMP-1, PICP, and ICTP.
  • Assessed composite cardiovascular endpoints over 44-month follow-up.

Main Results:

  • Microvascular density correlated with myocardial MMP-2/TIMP-1 ratio (r = -0.348, P = .009).
  • Plasma PICP/ICTP and MMP-2/TIMP-1 ratios were strong prognostic markers.
  • High plasma PICP/ICTP and MMP-2/TIMP-1 ratios independently predicted adverse cardiovascular outcomes (HRs 12.683 and 17.037).

Conclusions:

  • Myocardial MMP-2/TIMP-1 ratio elevation in HOCM may stem from microvascular rarefaction, not directly causing MF.
  • Elevated plasma PICP/ICTP and MMP-2/TIMP-1 ratios are independent predictors of adverse outcomes in HOCM patients.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
248
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
240
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
557
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
196
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
361